drugset / Trial / NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
NaSequentialOpen-labelTreatment
Summary
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
Timeline
- Start
- 2017-04-28
- Primary completion
- 2020-08-31
- Completion
- 2020-08-31
Outcome
Outcome not reported
Stopped: “Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the Phase 1b to advance to Phase 2.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VECABRUTINIB | Small molecule | 25 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 50 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 100 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 200 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 300 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 400 mg | Oral |
| Subject | VECABRUTINIB | Small molecule | 500 mg | Oral |